Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease

We conducted a phase 2 study in which patients undergoing allogeneic hematopoietic stem cell transplantation received tocilizumab in addition to standard immune suppression with tacrolimus and methotrexate for graft-versus-host disease prophylaxis. Thirty-five patients were enrolled between January...

Descripción completa

Detalles Bibliográficos
Autores principales: Drobyski, William R., Szabo, Aniko, Zhu, Fenlu, Keever-Taylor, Carolyn, Hebert, Kyle M., Dunn, Renee, Yim, Sharon, Johnson, Bryon, D’Souza, Anita, Eapen, Mary, Fenske, Timothy S., Hari, Parameswaran, Hamadani, Mehdi, Horowitz, Mary M., Rizzo, J. Douglas, Saber, Wael, Shah, Nirav, Shaw, Bronwen, Pasquini, Marcelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865423/
https://www.ncbi.nlm.nih.gov/pubmed/29351985
http://dx.doi.org/10.3324/haematol.2017.183434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865423/
https://www.ncbi.nlm.nih.gov/pubmed/29351985
http://dx.doi.org/10.3324/haematol.2017.183434

Ejemplares similares